Navigation Links
Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia

- Findings from an Otsuka Pharmaceutical Co, Ltd. Sponsored Study Presented at the American Psychiatric Association Annual Meeting -

SAN DIEGO, May 23, 2007 /PRNewswire/ -- In a six-week study in adolescents (13- 17 years old) with schizophrenia, the Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company atypical antipsychotic aripiprazole demonstrated significant improvement compared to placebo on the primary efficacy endpoint, Positive and Negative Syndrome Scale (PANSS) Total Score. In the findings first presented here at the 160th annual meeting of the American Psychiatric Association, approximately 85 percent of patients completed this six-week study.(1,2)

"Data on the management of schizophrenia in adolescents are limited," said Robert Findling, M.D., Director of Child and Adolescent Psychiatry, University Hospitals Case Medical Center, Cleveland, Ohio. "The findings from this study contribute important new information about schizophrenia in adolescents."

Study Design and Findings

The findings are from a six-week, randomized, double-blind, placebo- controlled study that evaluated the efficacy and safety of aripiprazole in adolescents, 13-17 years-old, with a primary diagnosis of schizophrenia. This study, sponsored by Otsuka Pharmaceutical Co., Ltd. and its U.S. subsidiary, Otsuka Pharmaceutical Development & Commercialization, Inc. (Princeton, NJ) was conducted at 101 centers in 13 countries with 302 ethnically diverse adolescents. After a minimum three-day washout period without any antipsychotic treatment, adolescents were randomly assigned to receive one of two fixed doses of aripiprazole [10 mg/day (n=100) or 30 mg/day (n=102)] or placebo (n=100). Aripiprazole was started at 2 mg/day and titrated to the target dose. The primary efficacy endpoint was the mean change from baseline to endpoint (Week Six) in the PANSS Total Score. Secondary endpoints included the PANSS
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
(Date:7/29/2014)... , July 29, 2014  Landauer, Inc. (NYSE: ... and environmental radiation measurement and monitoring, outsourced medical physics ... financial results for the fiscal third quarter 2014 after ... The Company will host a conference call ... a.m. Central Time (10 a.m. Eastern Time). Investors may ...
(Date:7/29/2014)... WASHINGTON , July 29, 2014 New ... in Medicare Part D by a projected $2.9 to ... by the actuarial firm Milliman released today by the ... Part D premiums could increase by as much as ... hepatitis C drugs, including Sovaldi and Olysio. ...
(Date:7/29/2014)... July 29, 2014 Numotion,s Board of Directors has ... will be the company,s new Chief Executive Officer. ... career at GE where he worked primarily for GE Healthcare ... to over $5 billion. His most recent position was as ... "I am thrilled to join Numotion," said Mike ...
Breaking Medicine Technology:Landauer, Inc. Sets Date and Time for Announcement of Fiscal Third Quarter 2014 Results 2New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Numotion Names Mike Swinford CEO 2
... 3, 2011 Nonin Medical, Inc., the inventor of ... a leader in noninvasive physiological monitoring, announced the worldwide ... Pulse Oximeter for medical monitoring manufacturers. ... wired pulse oximeter will provide a new level of ...
... Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR ) ... Senior Vice President of Research and Development, Cynthia Schwalm ... M.D., as Senior Vice President of Pharmacovigilance. These newly ... the Company prepares for the potential launch of its ...
Cached Medicine Technology:Nonin Medical Launches Low Power Xpod®, Model 3012LP, OEM Pulse Oximeter Globally 2Optimer Pharmaceuticals Expands Senior Management Team 2Optimer Pharmaceuticals Expands Senior Management Team 3Optimer Pharmaceuticals Expands Senior Management Team 4Optimer Pharmaceuticals Expands Senior Management Team 5
(Date:7/30/2014)... The Diabetes Daily Grind had its beginnings ... Ryan Fightmaster hope to gain attention for the website ... 26th of this year, Clour and Fightmaster started this ... diabetic life. By sharing stories on their lessons ... other diabetics will find ways to live with their ...
(Date:7/30/2014)... According to the Nasal Polyps Treatment Miracle book review recently ... people how to cure their nasal polyps permanently ... horrible truth about conventional treatments for nasal polyps. , ... will learn how to prevent symptoms related to nasal ... Nasal Polyps Treatment Miracle, as it is reviewed now by ...
(Date:7/30/2014)... The San Diego personal injury lawyers of The ... they are now offering free case reviews for individuals that ... , “Symptoms of asbestos exposure can take years to develop, ... years ago may just now be suffering from the ill ... Melinda J. Helbock A.P.C. “We want people to know that ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Nuanced Media, a ... announce the release of the Medical Web Design Trends of ... of research done across multiple agencies and the medical web ... are constantly changing as the industry grows. Therefore it is ... of ideas that consumers enjoy most. New trends are defined ...
(Date:7/29/2014)... 30, 2014 Saint Luke’s Medical ... awarded the Patient-Centered Medical Home 2011 Level 3 ... for Quality Assurance. Only one out of four ... Level 2, or Level 3 recognition. , Patients ... Medical Home report faster access to their doctors, ...
Breaking Medicine News(10 mins):Health News:Strangers Come Together to Form Diabetes Website: Real Messages of Hope and Inspiration 2Health News:Nasal Polyps Treatment Miracle Book Review Exposes Manuel Richards' Guide For Treating Nasal Polyps – Vkool.com 2Health News:Nasal Polyps Treatment Miracle Book Review Exposes Manuel Richards' Guide For Treating Nasal Polyps – Vkool.com 3Health News:The Law Office of Melinda J. Helbock A.P.C. Offers Case Evaluations for Possible Asbestos Claims 2Health News:Nuanced Media Releases "Medical Web Design Trends of 2014" Article 2Health News:Saint Luke’s Medical Group Awarded Patient-Centered Medical Home 2011 Level 3 Recognition 2
... of the disease among those vaccinated were no higher ... (HealthDay News) -- Rates of a rare neurodegenerative disease, ... last year were no higher than among the general ... syndrome were noted after widespread swine flu vaccination in ...
... April 13, 2010 Allergies have become a widespread ... are all increasingly prevalent. The reason? Excessive cleanliness is ... at the Universit de Montral Faculty of Medicine. ... pollution, processed foods, stress, tobacco use, etc. Yet our ...
... 2010) The human mouth is home to an estimated ... moist environment, along with hard tooth surfaces and soft tissues, ... of these bacteria are harmful and can form a film ... eventually more severe kinds of gum disease. Toothpaste ...
... ... features and prices of March special SEO offers, SEO-Peace.com management is pleased to extend its ... features to the client base. , ... Gurgaon, India (PRWEB) April 13, 2010 -- With SEO industry getting more and more ...
... , ... 1 out of every 6 men in the United States (1 in 3 in the ... against prostate cancer by registering for Little Red Door,s Unite 2 Fight Race Against Prostate ... Indianapolis, IN (PRWEB) ...
... with Williams syndrome have no social fear and appear ... 13 (HealthDay News) -- Children with a rare ... and with it, racial prejudice, a new study shows. ... the root cause of racial stereotyping. , French and ...
Cached Medicine News:Health News:Guillain-Barre Syndrome Very Rare After H1N1 Vaccine 2Health News:Guillain-Barre Syndrome Very Rare After H1N1 Vaccine 3Health News:Why are allergies increasing? 2Health News:Give dirty mouths a brush 2Health News:SEO-Peace.com Extends The March Special SEO Special Offers And Revise Many Services 2Health News:Registration Now Open for Little Red Door's Unite 2 Fight Race Against Prostate Cancer Saturday, July 10, 2010 2Health News:Kids With Rare Condition Lack Racial Prejudice 2
Molt periosteal elevator #9, 18.5 cm, 7-1/4"....
Periosteal elevator #9, 18 cm, 7"....
Full curve periosteal elevator - cervical - sharp, round tip, length 184 mm (7 1/4")....
... The Frontier Anterior Deformity System ... Kass, Moss Miami, and Isola ... thoracoscopic procedures to deliver unsurpassed versatility, ... the highest level of versatility for ...
Medicine Products: